FATE Q1 2022 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M+65.3% YoY

Gross Profit

-$54M-291.8% margin

Operating Income

-$74M-404.4% margin

Net Income

-$66M-356.7% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+7.9%

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$75M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$858M

Total Liabilities

$225M

Stockholders' Equity

$633M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$11M	+65.3%
Gross Profit	-$54M	-$34M	-59.4%
Operating Income	-$74M	-$46M	-61.1%
Net Income	-$66M	-$45M	-45.7%

Revenue Segments

Upfront Fee And Equity Premium

$6M100%